Source link : https://www.newshealth.biz/health-news/sglt2-inhibitors-add-to-glp-1s-cardio-kidney-benefits/
STOCKHOLM — In the treatment of type 2 diabetes, sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide 1 receptor agonists (GLP-1 RAs) show independent benefits that complement each other when combined in treating cardiovascular and kidney disease, a major analysis from the SGLT2 Inhibitor Meta-Analysis Cardio-Renal Trialists’ Consortium (SMART-C) showed. “These data represent the largest […]
Author : News Health
Publish date : 2024-06-03 06:42:46
Copyright for syndicated content belongs to the linked Source.
Categories